Advertisement
EDIT vs PROK
Which Stock Would AI Choose? Editas Medicine (EDIT) vs. ProKidney Corp. (PROK) Stock Comparison
Key Takeaways
- EDIT (Editas Medicine) is a preclinical-stage gene editing company, while PROK (ProKidney) is a late clinical-stage cell therapy company with an ongoing Phase 3 program.
- Both are pre-revenue biotechnology companies that rely on cash reserves; Editas reported roughly $123.6 million in cash at the end of Q1 2026, while ProKidney reported about $181.6 million at the end of Q2 2026.
- ProKidney offers nearer-term, clearly defined catalysts (pivotal topline results targeted for Q2 2027), whereas Editas carries earlier-stage, higher-risk but potentially higher-reward exposure.
- Analyst sentiment is mixed on EDIT (with both Buy and Sell ratings) and broadly constructive on PROK (consensus "Buy").
- Both names are high-beta, volatile small-cap biotechs whose relative performance has diverged sharply from the broader market in recent months.
- For deeper coverage, explore EDIT Major News and EDIT Today's Price Move, as well as PROK Major News and PROK Today's Price Move.
- To see which of these stocks an automated strategy currently favors, visit the curated Trending AI Robots page.
Introduction
Editas Medicine and ProKidney operate in different corners of the biotechnology sector, yet both attract traders seeking asymmetric returns from clinical-stage innovation. Editas is a pioneer in CRISPR gene editing now repositioned around an early-stage "in vivo" (inside-the-body) pipeline, while ProKidney is advancing a cell therapy through late-stage trials for chronic kidney disease. Comparing these two stocks highlights a recurring investor trade-off: nearer-term, catalyst-driven progress versus earlier-stage, higher-upside technology risk. This stock comparison is most relevant to biotech specialists, event-driven traders, and growth-oriented investors who can tolerate elevated volatility and binary clinical outcomes.
EDIT Overview and Recent Performance
EDIT (Editas Medicine, Inc.) develops gene editing medicines using CRISPR systems, with a current focus on in vivo therapies that edit genes directly inside the body. In late 2024 the company discontinued its reni-cel program and reduced its workforce by roughly 65%, returning it to a preclinical-stage business centered on its lead candidate, EDIT-401, a one-time therapy designed to lower LDL ("bad") cholesterol in patients with heterozygous familial hypercholesterolemia. Recent quarters have shown a materially narrower net loss driven by sharply lower operating expenses, reflecting the streamlined structure. Cash of about $123.6 million is expected to fund operations into the third quarter of 2027. Recent market activity has been volatile; the stock has drawn both upgrades and a Sell rating from different analysts, underscoring divided sentiment around an early-stage pipeline with no near-term clinical data readouts.
PROK Overview and Recent Performance
PROK (ProKidney Corp.) is a late clinical-stage cell therapy company focused on chronic kidney disease (CKD). Its lead candidate, rilparencel, is a first-in-class autologous cell therapy being evaluated in the Phase 3 PROACT 1 trial in patients with advanced CKD and type 2 diabetes. The company has aligned with the U.S. Food and Drug Administration (FDA) on an accelerated approval pathway using eGFR (estimated glomerular filtration rate) slope as a surrogate endpoint, with pivotal topline results expected in Q2 2027 and a potential Biologics License Application (BLA) submission in Q4 2027. Positive Phase 2 REGEN-007 data were presented in late 2025 and published in a peer-reviewed journal. With roughly $181.6 million in cash supporting operations into mid-2027, ProKidney has a more defined catalyst calendar, though its shares have underperformed the broader market in recent months and remain high-beta and volatile.
Trending AI Robots
Tickeron operates a large ecosystem of AI trading bots that monitor and trade thousands of different tickers across varied strategies, timeframes, and risk profiles. Because market conditions are constantly shifting, not every bot is well suited to the current environment. The Trending AI Robots page curates only the bots whose recent performance, consistency, and fit with prevailing conditions stand out. These automated systems differ in trading style, holding period, statistical profile, and the specific set of stocks they trade, giving investors a range of options rather than a one-size-fits-all approach. For readers interested in how an algorithmic strategy might position around names such as Editas Medicine or ProKidney, exploring the Trending AI Robots page can offer a data-driven complement to manual analysis.
Head-to-Head Comparison
The clearest contrast is development stage. PROK is in Phase 3 with regulatory alignment and defined milestones, giving it more measurable, time-bound catalysts. EDIT is preclinical, meaning its value hinges on laboratory-to-clinic translation that is inherently less certain but potentially more transformative. In business model terms, Editas is a platform-driven gene editing company, while ProKidney is a single-asset cell therapy play concentrated on one indication. Growth drivers differ accordingly: Editas depends on advancing EDIT-401 and securing partnerships, while ProKidney depends on enrollment completion and a successful pivotal readout. Risk factors also diverge — Editas faces execution and competitive risks in a crowded gene editing field, whereas ProKidney carries binary trial risk and a high cash-burn profile. Both stocks show high beta and significant drawdowns, and neither is yet profitable, making sentiment and liquidity key near-term drivers of relative performance.
Tickeron AI Verdict
Based on observable factors, Tickeron's AI would likely favor PROK over EDIT in the current environment. ProKidney's combination of a later development stage, FDA alignment on an accelerated approval pathway, a defined catalyst calendar, a broadly constructive analyst consensus, and a comparatively larger cash cushion supports relatively more consistent trend signals and clearer market positioning. Editas, by contrast, presents a less defined catalyst path and more divided analyst sentiment, which tends to produce choppier, less stable trends. That said, this assessment is probabilistic rather than definitive: both stocks carry substantial downside risk, and a favorable clinical or business-development event could shift relative positioning quickly.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EDIT is a Hold and PROK is a Hold.
EDIT's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for EDIT turned positive on October 27, 2026. Looking at past instances where EDIT's MACD turned positive, the stock continued to rise in 41 of 48 cases over the following month. The odds of a continued upward trend are 85%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +7.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 182 of 227 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 46 of 48 cases where EDIT's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 78 of 84 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.
EDIT moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for EDIT moved below the 200-day moving average on November 09, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
EDIT broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for EDIT entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 30 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.749) is normal, around the industry mean (3.498). P/E Ratio (-3.894) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. EDIT’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
PROK in downward trend: price dove below 50-day moving average on October 12, 2026
PROK moved below its 50-day moving average on October 12, 2026 date and that indicates a change from an upward trend to a downward trend. In 50 of 55 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PROK as a result. In 74 of 99 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 75%.
The Moving Average Convergence Divergence Histogram (MACD) for PROK turned negative on October 30, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 54 similar instances when the indicator turned negative. In 45 of the 54 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PROK declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for PROK entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where PROK's RSI Indicator exited the oversold zone, 24 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where PROK's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
Following a +7.98% 3-day Advance, the price is estimated to grow further. Considering data from situations where PROK advanced for three days, in 202 of 257 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
PROK may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 53 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.270) is normal, around the industry mean (3.498). P/E Ratio (-2.073) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (344.828) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 86 (best 1 - 100 worst), indicating slightly worse than average price growth. PROK’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PROK’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
EDIT | ||
|---|---|---|
OUTLOOK RATING 1..100 | 20 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 53 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 58 | |
P/E GROWTH RATING 1..100 | 30 | |
SEASONALITY SCORE 1..100 | 85 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| EDIT | PROK | |
|---|---|---|
| RSI ODDS (%) | N/A | 2 days ago 83% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 90% | 2 days ago 75% |
| MACD ODDS (%) | 2 days ago 85% | 2 days ago 83% |
| TrendWeek ODDS (%) | 2 days ago 90% | 2 days ago 76% |
| TrendMonth ODDS (%) | 2 days ago 89% | 2 days ago 81% |
| Advances ODDS (%) | 3 days ago 80% | 3 days ago 79% |
| Declines ODDS (%) | 10 days ago 90% | 9 days ago 86% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 72% |
| Aroon ODDS (%) | 2 days ago 88% | 2 days ago 88% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
EDIT’s FA Score shows that 1 FA rating(s) are green while PROK’s FA Score has 1 green FA rating(s).
- EDIT’s FA Score: 1 green, 4 red.
- PROK’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
EDIT’s TA Score shows that 2 TA indicator(s) are bullish while PROK’s TA Score has 4 bullish TA indicator(s).
- EDIT’s TA Score: 2 bullish, 7 bearish.
- PROK’s TA Score: 4 bullish, 5 bearish.
Price Growth
EDIT (@Biotechnology) experienced а -3.65% price change this week, while PROK (@Biotechnology) price change was +3.74% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
EDIT is expected to report earnings on Feb 25, 2027.
PROK is expected to report earnings on Mar 25, 2027.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
EDIT and
Correlation & Price change
A.I.dvisor indicates that over the last year, EDIT has been closely correlated with BEAM. These tickers have moved in lockstep 67% of the time. This A.I.-generated data suggests there is a high statistical probability that if EDIT jumps, then BEAM could also see price increases.
| Ticker / NAME | Correlation To EDIT | 1D Price Change % | ||
|---|---|---|---|---|
| EDIT | 100% | -8.91% | ||
| BEAM - EDIT | 67% Closely correlated | -6.92% | ||
| PRME - EDIT | 63% Loosely correlated | -9.30% | ||
| CRSP - EDIT | 63% Loosely correlated | -9.77% | ||
| SLDB - EDIT | 62% Loosely correlated | +2.14% | ||
| VYGR - EDIT | 61% Loosely correlated | -8.29% | ||
More | ||||
PROK and
Correlation & Price change
A.I.dvisor indicates that over the last year, PROK has been loosely correlated with RXRX. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if PROK jumps, then RXRX could also see price increases.
| Ticker / NAME | Correlation To PROK | 1D Price Change % | ||
|---|---|---|---|---|
| PROK | 100% | -3.48% | ||
| RXRX - PROK | 50% Loosely correlated | -6.70% | ||
| SANA - PROK | 49% Loosely correlated | -1.42% | ||
| EDIT - PROK | 46% Loosely correlated | -8.91% | ||
| NKTX - PROK | 45% Loosely correlated | -15.09% | ||
| TSHA - PROK | 44% Loosely correlated | -2.17% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| LIT.X | 3.464561 | 0.236335 | +7.32% |
| Lighter cryptocurrency | |||
| ALPINE.X | 0.283738 | -0.002453 | -0.86% |
| Alpine F1 Team Fan Token cryptocurrency | |||
| WIN.X | 0.000065 | -0.000001 | -1.64% |
| WINkLink cryptocurrency | |||
| AUCTION.X | 2.874088 | -0.082668 | -2.80% |
| Bounce Token cryptocurrency | |||
| FOR.X | 0.000042 | -0.001353 | -96.99% |
| ForTube cryptocurrency | |||